Terms: = Endocrine gland cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
186 results:
1. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
2. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
3. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract] [Full Text] [Related]
5. NET G3 vs NEC: p53 and rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract] [Full Text] [Related]
6. p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract] [Full Text] [Related]
7. Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
8. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract] [Full Text] [Related]
9. Combined treatment with
Huang S; Cui M; Wang R; Yang G; Wang N; Cui L; Ma G
Nucleosides Nucleotides Nucleic Acids; 2023; 42(9):731-742. PubMed ID: 36924446
[TBL] [Abstract] [Full Text] [Related]
10. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract] [Full Text] [Related]
11. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
Yang B; Quan Y; Zhao W; Ji Y; Yang X; Li J; Li Y; Liu X; Wang Y; Li Y
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2169282. PubMed ID: 36656085
[TBL] [Abstract] [Full Text] [Related]
12. The overexpressed regucalcin represses the growth via regulating diverse pathways linked to EGF signaling in human ovarian cancer SK-OV-3 cells: Involvement of extracellular regucalcin.
Yamaguchi M; Murata T; Ramos JW
Life Sci; 2023 Feb; 314():121328. PubMed ID: 36584916
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M
Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840
[TBL] [Abstract] [Full Text] [Related]
14. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience.
Gerratana L; Movarek M; Wehbe F; Katam N; Mahalingam D; Donahue J; Shah A; Chae YK; Mulcahy M; Tsarwhas D; Villaflor V; Kalyan A; Hussein M; Patel J; Chandra S; Platanias LC; Gradishar W; Cristofanilli M; Behdad A
JCO Precis Oncol; 2022 Jun; 6():e2100289. PubMed ID: 35772051
[TBL] [Abstract] [Full Text] [Related]
16. Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
Hollis RL; Meynert AM; Michie CO; Rye T; Churchman M; Hallas-Potts A; Croy I; McCluggage WG; Williams ARW; Bartos C; Iida Y; Okamoto A; Dougherty B; Barrett JC; March R; Matakidou A; Roxburgh P; Semple CA; Harkin DP; Kennedy R; Herrington CS; Gourley C
Clin Cancer Res; 2022 Aug; 28(16):3546-3556. PubMed ID: 35696721
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of a novel NUAK1 inhibitor against pancreatic cancer.
Seo MS; Jung KH; Kim K; Lee JE; Han BS; Ko S; Kim JH; Hong S; Lee SH; Hong SS
Biomed Pharmacother; 2022 Aug; 152():113241. PubMed ID: 35691157
[TBL] [Abstract] [Full Text] [Related]
18. Consensus Statement on Mandatory Measurements for Pancreatic cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
Pijnappel EN; Suurmeijer JA; Koerkamp BG; Kos M; Siveke JT; Salvia R; Ghaneh P; van Eijck CHJ; van Etten-Jamaludin FS; Abrams R; Brasiuniene B; Büchler MW; Casadei R; van Laethem JL; Berlin J; Boku N; Conroy T; Golcher H; Sinn M; Neoptolemos JP; van Tienhoven G; Besselink MG; Wilmink JW; van Laarhoven HWM
JAMA Oncol; 2022 Jun; 8(6):929-937. PubMed ID: 35446336
[TBL] [Abstract] [Full Text] [Related]
19. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Garcia-Carbonero R; Bazan-Peregrino M; Gil-Martín M; Álvarez R; Macarulla T; Riesco-Martinez MC; Verdaguer H; Guillén-Ponce C; Farrera-Sal M; Moreno R; Mato-Berciano A; Maliandi MV; Torres-Manjon S; Costa M; Del Pozo N; Martínez de Villarreal J; Real FX; Vidal N; Capella G; Alemany R; Blasi E; Blasco C; Cascalló M; Salazar R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338084
[TBL] [Abstract] [Full Text] [Related]
20. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract] [Full Text] [Related]
[Next]